ADAR1 Capital Management LLC lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 55.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,402 shares of the biotechnology company's stock after selling 90,000 shares during the quarter. Ascendis Pharma A/S accounts for 2.0% of ADAR1 Capital Management LLC's holdings, making the stock its 12th largest holding. ADAR1 Capital Management LLC owned 0.12% of Ascendis Pharma A/S worth $9,830,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Artisan Partners Limited Partnership raised its holdings in Ascendis Pharma A/S by 0.9% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after buying an additional 39,309 shares during the period. American Century Companies Inc. increased its position in shares of Ascendis Pharma A/S by 17.5% during the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock valued at $56,072,000 after acquiring an additional 60,548 shares during the last quarter. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $60,000. ARS Investment Partners LLC boosted its position in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company's stock worth $36,549,000 after purchasing an additional 2,369 shares during the period. Finally, New York State Common Retirement Fund increased its holdings in Ascendis Pharma A/S by 14.0% in the 4th quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock valued at $28,151,000 after purchasing an additional 25,164 shares during the last quarter.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on ASND shares. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective for the company. The Goldman Sachs Group boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, February 25th. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $204.64.
Read Our Latest Research Report on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Performance
ASND stock traded up $7.66 during midday trading on Friday, reaching $150.99. 426,300 shares of the company were exchanged, compared to its average volume of 478,482. The company has a market cap of $9.21 billion, a price-to-earnings ratio of -21.27 and a beta of 0.54. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37. The stock's 50-day simple moving average is $148.33 and its 200 day simple moving average is $137.70.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.
About Ascendis Pharma A/S
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
